Bengaluru, Karnataka, India, and Bridgewater, New Jersey, USA, November 16, 2026
Biocon Limited has received approval from the U.S. Food and Drug Administration (FDA) for Pebrilzo™ (pertuzumab-qcay) injection, a biosimilar to Perjeta® (pertuzumab), expanding its oncology portfolio and adding another treatment option for patients with HER2-positive breast cancer in the United States. The approval marks an important milestone for Biocon’s global biosimilars business, making Pebrilzo its fifth oncology biosimilar to receive U.S. FDA approval. Pertuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), a protein associated with the growth and proliferation of certain breast cancer cells. The approval follows the European regulatory progress of the product and strengthens Biocon’s position in the international oncology market. However, commercial availability in the United States is subject to the company’s previously announced licensing agreement with Genentech, which secures an anticipated launch in the third quarter of 2028.
FDA Approval Expands Treatment Options for HER2-Positive Breast Cancer
Pebrilzo (pertuzumab-qcay) is a HER2/neu receptor antagonist indicated for use in combination with other cancer medicines across multiple stages of HER2-positive breast cancer. In patients with metastatic breast cancer, it is indicated alongside trastuzumab and docetaxel for adults who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease. For early-stage disease, Pebrilzo can be used with trastuzumab and chemotherapy as part of neoadjuvant treatment for adults with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, including certain patients with larger tumours or lymph-node involvement. It is also indicated for adjuvant treatment of adults with HER2-positive early breast cancer who have a high risk of recurrence. HER2-positive breast cancer is characterised by overexpression of HER2 protein or amplification of the HER2 gene, which can drive tumour growth. By binding to HER2 receptors, pertuzumab interferes with signalling involved in cancer-cell proliferation. The medicine is administered by intravenous infusion and is used as part of combination treatment rather than as a standalone therapy for these indications.
Biosimilar Evidence Supports Regulatory Approval
The FDA approval was supported by a comprehensive evidence package involving structural and functional analytical characterisation, analytical similarity assessments and comparative clinical pharmacokinetic data. These evaluations demonstrated that Pebrilzo is highly similar to the reference biologic, Perjeta, with no clinically meaningful differences in quality, safety, efficacy or immunogenicity. Biosimilars are biological medicines developed to be highly similar to an already approved reference product, with no clinically meaningful differences in their performance. The regulatory assessment considers analytical and clinical evidence to establish this similarity. According to Shreehas Tambe, CEO and Managing Director of Biocon Limited, the approval represents another milestone in the company’s efforts to expand access to high-quality and affordable biologic medicines. The company believes that its expanding biosimilar portfolio can contribute to greater treatment choice and competition in oncology care. The approval also follows the positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2026, recommending marketing authorization for the pertuzumab biosimilar in Europe. The European Commission subsequently granted marketing authorization in November 2026.
Commercial Launch Planned for 2028 as Oncology Portfolio Grows
Although the FDA has approved Pebrilzo, the anticipated U.S. commercial launch is scheduled for the third quarter of calendar year 2028. This timeline follows a global settlement and licensing agreement between Biocon and Genentech that resolved pending patent disputes and established the earliest licensed launch date for the product in the United States. The agreement is an important consideration for healthcare providers and patients because regulatory approval does not necessarily mean immediate market availability. Pebrilzo will join Biocon’s existing U.S. oncology portfolio, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb) and Aukelso® (denosumab-kyqq). The company is also developing proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, extending its research and development activities across HER2-targeted therapies and immuno-oncology. The FDA-approved prescribing information includes important safety warnings for pertuzumab products. These include left ventricular dysfunction and embryo-fetal toxicity. Cardiac function must be assessed before and during treatment, and patients should be counselled about potential risks during pregnancy. Infusion-related reactions and serious hypersensitivity reactions are additional precautions requiring appropriate clinical monitoring.
The approval represents a significant addition to Biocon’s oncology business and reflects the growing role of biosimilars in expanding access to established biologic treatments. Pebrilzo is FDA-approved, but its U.S. launch remains subject to the agreed commercial timeline. Its introduction is expected to broaden Biocon’s presence in HER2-positive breast cancer treatment while contributing to the evolving biosimilar landscape in oncology.
Source: Biocon press release



